These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 35301609)
1. Association of RAS/BRAF Status and Prognosis of Metastatic Colorectal Cancer: Analysis of 1002 Consecutive Cases. Tang W; Liu Y; Ji M; Liu T; Chen Y; Zhuang A; Mao Y; Chang W; Wei Y; Ren L; Xu J Ann Surg Oncol; 2022 Jun; 29(6):3593-3603. PubMed ID: 35301609 [TBL] [Abstract][Full Text] [Related]
2. Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome. Thomsen M; Skovlund E; Sorbye H; Bolstad N; Nustad KJ; Glimelius B; Pfeiffer P; Kure EH; Johansen JS; Tveit KM; Christoffersen T; Guren TK Br J Cancer; 2018 Jun; 118(12):1609-1616. PubMed ID: 29872151 [TBL] [Abstract][Full Text] [Related]
4. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study. Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295 [TBL] [Abstract][Full Text] [Related]
5. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence. Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183 [TBL] [Abstract][Full Text] [Related]
6. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status. Taieb J; Kourie HR; Emile JF; Le Malicot K; Balogoun R; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Mulot C; Bouché O; Aparicio T; Michel P; Thaler J; Bridgewater J; Van Cutsem E; Perkins G; Lepage C; Salazar R; Laurent-Puig P; JAMA Oncol; 2018 Jul; 4(7):e173695. PubMed ID: 29167892 [TBL] [Abstract][Full Text] [Related]
7. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer. Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910 [TBL] [Abstract][Full Text] [Related]
8. High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort. Sorbye H; Dragomir A; Sundström M; Pfeiffer P; Thunberg U; Bergfors M; Aasebø K; Eide GE; Ponten F; Qvortrup C; Glimelius B PLoS One; 2015; 10(6):e0131046. PubMed ID: 26121270 [TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study. Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218 [TBL] [Abstract][Full Text] [Related]
10. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status. Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990 [TBL] [Abstract][Full Text] [Related]
11. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Wang F; Huang YS; Wu HX; Wang ZX; Jin Y; Yao YC; Chen YX; Zhao Q; Chen S; He MM; Luo HY; Qiu MZ; Wang DS; Wang FH; Xu M; Li YH; Xu RH Gut; 2022 Jul; 71(7):1340-1349. PubMed ID: 34489309 [TBL] [Abstract][Full Text] [Related]
12. Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study. Uutela A; Osterlund E; Halonen P; Kallio R; Ålgars A; Salminen T; Lamminmäki A; Soveri LM; Ristamäki R; Lehtomäki K; Stedt H; Heervä E; Muhonen T; Kononen J; Nordin A; Ovissi A; Kytölä S; Keinänen M; Sundström J; Nieminen L; Mäkinen MJ; Kuopio T; Ristimäki A; Isoniemi H; Osterlund P Br J Cancer; 2022 Sep; 127(4):686-694. PubMed ID: 35610367 [TBL] [Abstract][Full Text] [Related]
13. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Yaeger R; Cercek A; Chou JF; Sylvester BE; Kemeny NE; Hechtman JF; Ladanyi M; Rosen N; Weiser MR; Capanu M; Solit DB; D'Angelica MI; Vakiani E; Saltz LB Cancer; 2014 Aug; 120(15):2316-24. PubMed ID: 24737664 [TBL] [Abstract][Full Text] [Related]
14. Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan. Ikoma T; Shimokawa M; Kotaka M; Matsumoto T; Nagai H; Boku S; Shibata N; Yasui H; Satake H BMC Cancer; 2021 May; 21(1):518. PubMed ID: 33962575 [TBL] [Abstract][Full Text] [Related]
15. Mutation Status and Prognostic Value of KRAS and BRAF in Southeast Iranian Colorectal Cancer Patients: First Report from Southeast of Iran. Yari A; Samoudi A; Afzali A; Karam ZM; Karimaldini NK; Abadi MFS; Ziasistani M; Zangouey MR; Dabiri S J Gastrointest Cancer; 2021 Jun; 52(2):557-568. PubMed ID: 32495109 [TBL] [Abstract][Full Text] [Related]
16. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525 [TBL] [Abstract][Full Text] [Related]
17. Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis. Tosi F; Magni E; Amatu A; Mauri G; Bencardino K; Truini M; Veronese S; De Carlis L; Ferrari G; Nichelatti M; Sartore-Bianchi A; Siena S Clin Colorectal Cancer; 2017 Sep; 16(3):e153-e163. PubMed ID: 28216246 [TBL] [Abstract][Full Text] [Related]
18. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Schirripa M; Bergamo F; Cremolini C; Casagrande M; Lonardi S; Aprile G; Yang D; Marmorino F; Pasquini G; Sensi E; Lupi C; De Maglio G; Borrelli N; Pizzolitto S; Fasola G; Bertorelle R; Rugge M; Fontanini G; Zagonel V; Loupakis F; Falcone A Br J Cancer; 2015 Jun; 112(12):1921-8. PubMed ID: 25942399 [TBL] [Abstract][Full Text] [Related]
19. Mutation Status of Kawaguchi Y; Kopetz S; Newhook TE; De Bellis M; Chun YS; Tzeng CD; Aloia TA; Vauthey JN Clin Cancer Res; 2019 Oct; 25(19):5843-5851. PubMed ID: 31221662 [TBL] [Abstract][Full Text] [Related]